Emerging studies suggest Retatru tide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to represent a significant advancement for obesity loss . Initial patient tests have demonstrated considerable decreases in body fat , potentially outperforming other weight-loss medications . Nevertheless , furth